Trial · NCT02147834
Effectiveness of Ranolazine on Reducing Chest Pain in Patients With Blockage But no Stents
NCT02147834, Phase 2, Terminated, North Florida Foundation for Research and Education; results first posted 2019-06-11
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effectiveness of Ranolazine on Reducing Chest Pain in Patients With Blockage But no Stents. Trials, record NCT02147834. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02147834
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effectiveness of Ranolazine on Reducing Chest Pain in Patients With Blockage But no Stents
- NCT number
- NCT02147834
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 5 participants, actual
- Lead sponsor
- North Florida Foundation for Research and Education
- Conditions
- Angina
- Interventions
- Ranolazine, Sugar pill
- First posted
- 2014-05-28
- Last updated
- 2019-06-11
- Results first posted
- 2019-06-11
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Seattle Angina Questionnaire Score Change From Baseline to Month 4 | Change in baseline to month 4 | The Seattle Angina Questionnaire is a valid and reliable instrument that measures five clinically important dimensions of health in patients with coronary artery disease (physical limitation, anginal stability, anginal frequency, treatment satisfaction, and disease perception). |
| Secondary | Subjective Well Being | Compare from baseline to month 4 | overall feeling of well being determined from rating of excellent, good, fair or poor at baseline compared to same at month 4 |
| Secondary | Ischemia Driven Revascularization or Hospitalization | 4 month | frequency of the number of reported adverse events for ischemia driven revascularization or hospitalization |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Seattle Angina Questionnaire Score Change From Baseline to Month 4 | Change in baseline to month 4 | The investigator ended this project early due to futility. Do data was analyzed. | ||
| SECONDARY | Subjective Well Being | Compare from baseline to month 4 | The investigator ended this study early due to futility. no data was analyzed. | ||
| SECONDARY | Ischemia Driven Revascularization or Hospitalization | 4 month | The investigator ended this study early due to futility. No data was analyzed. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Ranolazine | 3 | |
| Overall Study | STARTED | Sugar Pill | 2 | |
| Overall Study | COMPLETED | Ranolazine | 3 | |
| Overall Study | COMPLETED | Sugar Pill | 2 | |
| Overall Study | NOT COMPLETED | Ranolazine | 0 | |
| Overall Study | NOT COMPLETED | Sugar Pill | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Ranolazine | ||
| Total, all-cause mortality | Sugar Pill | ||
| Total, other adverse events | Ranolazine | 0 | 3 |
| Total, other adverse events | Sugar Pill | 0 | 2 |
| Total, serious adverse events | Ranolazine | 0 | 3 |
| Total, serious adverse events | Sugar Pill | 0 | 2 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Ranolazine vs Sugar Pill: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02147834
GET https://conductscience.org/api/trials/v1/NCT02147834/registered